![]() |
Name |
Chaetomugilin E
|
Molecular Formula | C24H29ClO6 | |
IUPAC Name* |
(1S,10S,12R,13R,14R,17R)-8-chloro-12-methoxy-10,13,14-trimethyl-5-[(E,3S)-3-methylpent-1-enyl]-4,11,15-trioxatetracyclo[8.7.0.02,7.012,17]heptadeca-2,5,7-triene-9,16-dione
|
|
SMILES |
CC[C@H](C)/C=C/C1=CC2=C(C(=O)[C@@]3([C@H](C2=CO1)[C@H]4C(=O)O[C@@H]([C@H]([C@]4(O3)OC)C)C)C)Cl
|
|
InChI |
InChI=1S/C24H29ClO6/c1-7-12(2)8-9-15-10-16-17(11-29-15)18-19-22(27)30-14(4)13(3)24(19,28-6)31-23(18,5)21(26)20(16)25/h8-14,18-19H,7H2,1-6H3/b9-8+/t12-,13+,14+,18+,19-,23-,24+/m0/s1
|
|
InChIKey |
XGXRGYADYVZCTF-OPLDBLFRSA-N
|
|
Synonyms |
Chaetomugilin E; CHEMBL3621757; (1S,10S,12R,13R,14R,17R)-8-chloro-12-methoxy-10,13,14-trimethyl-5-[(E,3S)-3-methylpent-1-enyl]-4,11,15-trioxatetracyclo[8.7.0.02,7.012,17]heptadeca-2,5,7-triene-9,16-dione; 1098081-40-3
|
|
CAS | NA | |
PubChem CID | 25148535 | |
ChEMBL ID | CHEMBL3621757 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 448.9 | ALogp: | 3.8 |
HBD: | 0 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 71.1 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.568 |
Caco-2 Permeability: | -4.607 | MDCK Permeability: | 0.00001320 |
Pgp-inhibitor: | 0.051 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.299 |
30% Bioavailability (F30%): | 0.958 |
Blood-Brain-Barrier Penetration (BBB): | 0.983 | Plasma Protein Binding (PPB): | 77.93% |
Volume Distribution (VD): | 2.505 | Fu: | 18.90% |
CYP1A2-inhibitor: | 0.907 | CYP1A2-substrate: | 0.838 |
CYP2C19-inhibitor: | 0.862 | CYP2C19-substrate: | 0.77 |
CYP2C9-inhibitor: | 0.761 | CYP2C9-substrate: | 0.014 |
CYP2D6-inhibitor: | 0.816 | CYP2D6-substrate: | 0.05 |
CYP3A4-inhibitor: | 0.953 | CYP3A4-substrate: | 0.685 |
Clearance (CL): | 8.304 | Half-life (T1/2): | 0.064 |
hERG Blockers: | 0.024 | Human Hepatotoxicity (H-HT): | 0.99 |
Drug-inuced Liver Injury (DILI): | 0.944 | AMES Toxicity: | 0.143 |
Rat Oral Acute Toxicity: | 0.857 | Maximum Recommended Daily Dose: | 0.813 |
Skin Sensitization: | 0.919 | Carcinogencity: | 0.75 |
Eye Corrosion: | 0.195 | Eye Irritation: | 0.072 |
Respiratory Toxicity: | 0.986 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002532 | ![]() |
0.813 | D0C1SF | ![]() |
0.211 | ||
ENC002501 | ![]() |
0.670 | D0K7LU | ![]() |
0.198 | ||
ENC004258 | ![]() |
0.637 | D09HNR | ![]() |
0.180 | ||
ENC002529 | ![]() |
0.598 | D06WTZ | ![]() |
0.180 | ||
ENC005231 | ![]() |
0.585 | D0G6AB | ![]() |
0.177 | ||
ENC002613 | ![]() |
0.558 | D0E9KA | ![]() |
0.177 | ||
ENC002612 | ![]() |
0.458 | D00OAY | ![]() |
0.177 | ||
ENC002611 | ![]() |
0.451 | D0VA0I | ![]() |
0.176 | ||
ENC005844 | ![]() |
0.450 | D0F4ZY | ![]() |
0.175 | ||
ENC005878 | ![]() |
0.450 | D0L7LC | ![]() |
0.174 |